Navigation Links
Amylin, Lilly and Alkermes Announce Receipt of Complete Response Letter from FDA for BYDUREON™
Date:10/19/2010

eatment of type 2 diabetes based on Alkermes' proprietary Medisorb® technology for long-acting medications. BYDUREON is not currently approved by any regulatory agencies.

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego.

Through a long-standing commitment to diabetes care, Lilly provides patients with breakthrough treatments that enable them to live longer, healthier and fuller lives. Since 1923, Lilly has been the industry leader in pioneering therapies to help healthcare professionals improve the lives of people with diabetes, and research continues on innovative medicines to address the unmet needs of patients.

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs.

Alkermes, Inc. is a fully integrated biotechnology company committed to developing innovative medicines to improve patients' lives. Alkermes' robust pipeline includes extended-release injectable, pulmonary and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction and diabetes. Headquartered in Waltham, Mass., Alkermes has a research facility in Massachusetts and a commercial manufacturing facility in Ohio.

This press release contains forward-looking statements about Amylin, Lilly and Alkermes. Actual results could differ materially from those discu
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; Alkermes, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Calif. , Feb. 27, 2015  Finesse expands office ... Finesse Solutions announced the expansion of its operations ... is planned for mid-March and access for customers is ... the A-563, and located adjacent to the current office, ... the Finesse automation engineering team and allow Finesse to bring ...
(Date:2/26/2015)... 26, 2015  AbbVie (NYSE: ABBV ... in its neuroscience and oncology development programs have ... American Academy of Neurology annual meeting in ... 18-25. The accepted abstracts feature results from studies ... investigational treatments in AbbVie,s pipeline. Presentations will include ...
(Date:2/26/2015)... 26, 2015  Mobility Ventures LLC, an AM General ... of America (NYSE: BAC ) that will ... of the revolutionary MV-1 - - the world,s first ... up to provide safe and comfortable transportation for all ... loan to purchase a new MV-1 vehicle at the ...
Breaking Medicine Technology:New Finesse Office in United Kingdom 2AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 2AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 3AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 4AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 5AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 6AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 7Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 2Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 3
... VIEW, Calif., July 24 Alexza,Pharmaceuticals, Inc. ... it has initiated,its second Phase 3 clinical ... inhalation product candidate being developed for the ... or bipolar disorder.,Alexza believes the novel, non-invasive ...
... Program Speeds Oncology Patient Accrual, DENVER, ... Management,Organization (RMO), has contracted with five leading ... services for their,clinical trials using the Just-in-Time ... following disease indications: follicular Non-Hodgkin,s,Lymphoma, Metastatic Breast ...
Cached Medicine Technology:Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 2Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 3Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 4Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 5Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 6Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials 2
(Date:2/28/2015)... Malaysia (PRWEB) February 28, 2015 The ... all across Malaysia into one platform and gears towards ... , A series of group talks in smaller ... like Nation Building, Education, Personal Development, Leadership, Entrepreneurship, Healthcare, ... and raise awareness of Malaysian youths. , ...
(Date:2/28/2015)... 28, 2015 Gerald “Solutionman” Haman surveyed ... or barriers to innovative thinking. “The #1 block ... lack of tools,” reports Haman, who created the Thinkubator ... of people felt that they did not have enough ... and resources to stimulate innovation. , Solutionman’s monthly “Accelerating ...
(Date:2/28/2015)... March—also known as National Brain Injury ... and others that suspected head injuries, especially concussions, ... , Concussions are a form of traumatic brain ... There are 1.6-3.8 million sports-related concussions per year. ... is a brain injury. Many athletes suffer knee ...
(Date:2/28/2015)... A study out of the University of Oxford ... the treatment of a hereditary ocular condition that leads ... Dr. Robert MacLaren, professor of ophthalmology at the University ... on January 16, 2014 , the study treated six ... mostly affects men and leads to the degeneration of ...
(Date:2/28/2015)... Louis, MO (PRWEB) February 28, 2015 ... leading provider of outsourced sales, marketing and supply ... their client, BIOTA Botanicals, is bringing its award ... Celebrated worldwide, BIOTA Botanicals’ products are specifically created ... herbal care experts, BIOTA is committed to marrying ...
Breaking Medicine News(10 mins):Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 3Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 4Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 2Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 3Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 2Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 3Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3
... Center for Photomedicine at Massachusetts General Hospital (MGH) ... imaging technology optical coherence tomography (OCT) that can ... disease. In a Nature Medicine ... how microOCT which provides 10 times greater ...
... has been known to cause an assortment of health problems, ... for Sports Medicine,s (AOSSM) Annual Meeting in San Diego today, ... chance of muscle injuries in athletes, specifically NFL football players. ... vitamin D insufficiency. African American players and players who suffered ...
... , SUNDAY, July 10 (HealthDay News) -- ... for many Americans, but mixing the two can be ... warns. Alcohol is involved in half of all ... the NIAAA, which outlined a number of potentially dangerous ...
... have identified a group of patients who may have increased ... that usually develops because a teenager or young adult has ... study will be presented at the annual meeting of the ... in San Diego. "The conclusion from this study is ...
... SATURDAY, July 9 (HealthDay News) -- A bit of ... get enough exercise during the summer, experts say. To ... of one hour of physical activity a day, suggested Dr. ... of Alabama at Birmingham. "Set an expectation of doing ...
... Surgery have found that in comparison to open surgery, ... to arthritis produces similar outcomes in terms of repairing ... published in the July 2011 TK issue of the ... of patients with more typical hip impingement, arthroscopic approaches ...
Cached Medicine News:Health News:High-resolution imaging technology reveals cellular details of coronary arteries 2Health News:Study identifies patients who should not undergo surgery for a snapping hip tendon 2Health News:Study identifies patients who should not undergo surgery for a snapping hip tendon 3Health News:Help Your Kids Stay in Shape This Summer 2Health News:Arthroscopy and open surgery are equally efficacious in treating common hip problem in most patients 2Health News:Arthroscopy and open surgery are equally efficacious in treating common hip problem in most patients 3
ROC XS is a polyethylene implant used for soft tissue reattachment to bone. The umbrella-like deployment of this anchor provides increased fixation strength. This anchor is easy-to-insert using the R...
The Knotless Anchor, a titanium alloy implant, is used for soft tissue reattachment to bone. The Knotless Anchor is indicated for open and arthroscopic Bankart repairs....
... The Linvatec 5mm Super Revo Suture Anchor ... arthroscopic or a mini-open rotator cuff repair. ... the anchor is pre-threaded with two #2 ... pitfalls of suture management are avoided with ...
The 4mm diameter Revo suture anchor is designed primarily for arthroscopic and open rotator cuff repair. Additional applications include other shoulder repair procedures, as well as use in knees and ...
Medicine Products: